Over 537 million people globally suffer from diabetes, with 227 million in Asia Pacific. More than half may develop diabetic ...

Valo Health’s Rho kinase (ROCK) 1 and 2 inhibitor has failed to reduce the severity of diabetic retinopathy in a phase 2 ...

OCX-063 is under clinical development by OccuRx and currently in Phase I for Diabetic Retinopathy. According to GlobalData, Phase I drugs for Diabetic Retinopathy have a 78% phase transition success ...

Striking a balance between innovation and responsibility is imperative. By prioritizing transparency, adhering to robust ...

Though the day, on Monday, a free eye check-up camp was held, in course of which visitors were checked for dry eyes ...

Empagliflozin initiation is not associated with incident nonproliferative diabetic retinopathy (NPDR) compared with ...

APX-3330 is under clinical development by Opus Genetics and currently in Phase II for Non-Proliferative Diabetic Retinopathy (NPDR).

下面我就来说说对糖尿病患者视力影响最严重、生活质量影响最明显的几种眼病。